Immunology Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Case Report - Immunology Case Reports (2022) Volume 5, Issue 2

A case report and review of the literature of immune checkpoint inhibitor in a patient with small-cell lung cancer.

Masaye Takida*

Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Tsukimi, Japan

*Corresponding Author:
Masaye Takida
Department of Respiratory Medicine
Japanese Red Cross Fukui Hospital
Tsukimi, Japan

Received: 02-Mar-2022, Manuscript No. AAICR-22-57701; Editor assigned: 04-Mar-2022, Pre QC No. AAICR-22-57701(PQ); Reviewed: 18-Mar-2022, QC No. AAICR-22-57701; Revised: 21-Mar-2022, Manuscript No. AAICR-22-57701(R); Published: 28-Mar-2022, DOI:10.35841/ DOI:10.35841/ aaicr-5.2.108

Citation: Takida M. A case report and review of the literature of immune checkpoint inhibitor in a patient with small-cell lung cancer. Immunol Case Rep. 2022;5(2):108

Visit for more related articles at Immunology Case Reports


Para neoplastic neurological disorder (PNS) is related to malignancies, including little cell cellular breakdown in the lungs. As of late, PNS cases among patients with little cell cellular breakdown in the lungs (SCLC) prompted by insusceptible designated spot inhibitors have expanded. We in this report a 66-year-elderly person with SCLC who created bewilderment, dysphagia, and walk unsettling influence after three courses of treatment with atezolizumab. Cerebrum attractive reverberation imaging uncovered an extreme focus region in the two-sided fleeting projections. Blood test results were positive for hostile to Hu and against Zic4 antibodies, which prompted the conclusion of limbic encephalitis as PNS. A few side effects improved with intravenous organization of steroids and immunoglobulin’s.


Immune, Cell cellular breakdown in the lungs, Patient, Immunoglobulin's, Neurological disorder.


Para neoplastic neurological condition (PNS) is brought about by an immune system process that creates in patients with a threat. Resistant designated spot inhibitors (ICIs) are viable therapy choices for patients with malignancies, including little cell cellular breakdown in the lungs (SCLC). Be that as it may, ICIs cause incendiary incidental effects by expanding the action of the resistant framework. In this manner, ICIs are attempted to be a gamble factor for PNS. As a matter of fact, instances of PNS prompted by ICIs have as of late expanded. In this, we report an instance of ICI-instigated limbic encephalitis created in a patient with SCLC. The current report recommends that clinicians ought to think about PNS when patients foster neurological side effects after ICI inception [1].

Case Report

A 66-year-elderly person with a background marked by smoking for a considerable length of time was alluded to our medical clinic for strange chest radiograph discoveries. The patient had a background marked by bronchial asthma, without any set of experiences of immune system illnesses. Registered tomography (CT) and positron discharge tomography with 18F-fluorodeoxyglucose uncovered a cancer mass in the right hilum, hilar and mediastina lymph hub expanding, and various lung metastases. Mind attractive reverberation imaging (MRI) showed no strange finding. Obsessive discoveries of bronchoscopy of the essential growth uncovered SCLC. Consequently, the patient was determined to have broad illness SCLC (ED-SCLC) and was treated with carboplatin and etoposide, and atezolizumab was started as first-line chemotherapy. Treatment prompted a total reaction [2].

The patient created bewilderment after three courses of chemotherapy north of 2 months. Despite the fact that development with next to no treatment was preceded, the bewilderment deteriorated with trance state. Dysphagia and step unsettling influences because of muscle shortcoming additionally grew; nonetheless, we were unable to perform definite neurological assessment attributable to the condition of his cognizance. Liquid lessened reversal recuperation (FLAIR) imaging of mind MRI after trance state improvement showed a focused energy region in the reciprocal transient projections. Besides, against Hu and hostile to Zic4 antibodies were profoundly recognized in the blood test. The cerebrospinal liquid assessment showed no proof of cancer cells or disease, including herpes simplex infection and varicella-zoster infection [3].

In light of these outcomes, hostile to Hu and against Zic4 antibodies-positive limbic encephalitis as PNS was given as the last finding. As steroid beat treatment was started, the unsettling influence of cognizance moved along. Notwithstanding, dysphagia and stride unsettling influence showed no improvement. Because of this, intravenous immunoglobulin (IVIG) treatment was likewise started prompting improvement of dysphagia, however not with stride aggravation. Mind MRI discoveries at 90 days after commencement of steroid treatment likewise improved somewhat, and blood test around then showed hostile to Zic4 immune response pessimism with against Hu neutralizer steadiness. At the hour of composing, a half year has passed since the advancement of limbic encephalitis, and the neurological side effects didn't decline. Moreover, a total reaction was noticed.

In the current case, limbic encephalitis as PNS was analyzed because of the accompanying reasons;

1) Anti-Hu and hostile to Zic4 antibodies were identified in the serum at the beginning of neurological side effects.

2) SCLC was introduced at the beginning of neurological side effects.

3) SCLC is one of the most unequivocally connected cancers with PNS.

4) MRI uncovered an extreme focus region in the respective transient flaps, which was steady with limbic encephalitis.

5) No other conceivable reason was found for confusion, like focal sensory system metastasis, stroke, or metabolic problems in blood tests and mind MRI [4].

6) No proof of meningeal carcinomatosis or contamination in the cerebrospinal liquid was found.

Hostile to Hu counter acting agent is an auto-immune response related with limbic encephalitis and tangible neuropathy. Against Zic4 immune response is likewise connected with limbic encephalitis, cerebellar brokenness, and tactile neuropathy. The MRI discoveries of the patient were reliable with those of limbic encephalitis. Along these lines, the neurological side effects, unsettling influence of cognizance, dysphagia, and stride aggravation were viewed as brought about by against Hu and hostile to Zic4 antibodies-positive limbic encephalitis as PNS in the current case [5].


Past reports additionally showed a few kinds of neurological side effects of PNS in SCLC patients treated with ICIs. Notwithstanding, an impediment of the current case is the non-assessment of the neuronal cell surface antibodies. Neuronal cell surface neutralizer interceded immune system encephalitis ought to be considered as a differential finding. A finding of against Hu and hostile to Zic4 antibodies-positive limbic encephalitis might be almost certain, in the event that neuronal cell surface antibodies, for example, hostile to n-methyl-D-aspartate (NMDA) receptor immune response, are wellspring to be negative.


  1. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. New Eng J Med. 2003;349(16):1543-54.
  2. Indexed at, Google Scholar, Cross Ref

  3. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. The Lancet Neurol. 2008;7(4):327-40.
  4. Indexed at, Google Scholar, Cross Ref

  5. Horn L, Mansfield AS, Szcz?sna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. New Eng J Med. 2018;379(23):2220-9.
  6. Indexed at, Google Scholar, Cross Ref

  7. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New Eng J Med. 2018;378(2):158-68.
  8. Indexed at, Google Scholar, Cross Ref

  9. Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clinical Oncol. 2019;16(9):535-48.
  10. Indexed at, Google Scholar, Cross Ref

Get the App